If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDrax Regulatory News (DRX)

Share Price Information for Drax (DRX)

Share Price is delayed by 15 minutes
Get Live Data
758.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.00 (0.133%)
Market Cap: £2.55b
DRX Live PriceLast checked at - London Stock Exchange

Intraday Drax Share Chart

2022 Performance Awards - EPS Condition

19 Apr 2022 12:00

RNS Number : 5995I
Drax Group PLC
19 April 2022
 

19 April 2022

Drax Group plc

("Drax" or the "Group"; Symbol:DRX)

 

2022 Performance Awards - EPS Condition

At the time of publishing the annual report for the financial year ended 31 December 2021, Drax advised it would be separately determining, and thereafter releasing details of, the Cumulative Adjusted Earnings per Share performance condition which applies to grants made to PDMRs and other employees in the 2022 financial year.

The vesting of awards granted are subject to satisfying two performance criteria over the financial years 2022, 2023 and 2024. 50% of the awards will be measured based on Relative Total Shareholder Return relative to the FTSE-350, and the remaining 50% will be measured based on Cumulative Adjusted Earnings per Share.

Following a meeting of the Remuneration Committee, the proposed Cumulative Adjusted EPS target for 2022 has been agreed. The EPS target was set after considering the company's internal forecasts, market expectations and sector peers.

 

 

Threshold

Target

Maximum

239.5p

266.1p

292.7p

 

 

BASIS OF VESTING

Performance

Target

% of Award Vesting(of EPS performance condition)

Below threshold

0%

Threshold

239.5p

25%

Maximum

292.7p

100%

 

Vesting between the threshold and maximum will be on a straight-line basis.

The EPS target is 'Adjusted EPS', derived from Adjusted Results as reported in the Company's audited financial statements. Instances where such adjustments might apply include acquisition and restructuring costs, asset obsolescence charges and certain remeasurements on derivative contracts.

There may arise circumstances during the performance period where adjustment or discretion is applied by the Remuneration Committee by reference to exceptional items and the Remuneration Policy. The application of such adjustments would be considered during and upon completion of the performance cycle. In making their assessment, the Remuneration Committee will take into account appropriate advice (for example from our auditors, Remuneration Committee advisers or the Audit Committee) and also give due consideration to the shareholder experience. The Remuneration Committee would also take into account exceptional and unforeseen circumstances, including wider considerations such as the prevailing market environment, in assessing the appropriate level of vesting judged against the performance of the Company and management at the end of the performance period.

Total Shareholder Return relative to the FTSE-350 will be measured over the three-year period (2022-2024) consistent with the approach previously approved by shareholders.

The Remuneration Committee of Drax considers that attaining outturn at the top end of the range would represent strong performance considering the uncertain economic circumstances and the challenges to the broader economy. 

 

Ends

 

Enquiries:

Drax Investor Relations: Mark Strafford

mark.strafford@drax.com 

+44 (0) 7730 763 949

Brett Gladden, Group Company Secretarybrett.gladden@drax.com+44 (0)7936 362586

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFEFSUEESEEL
Date   Source Headline
15th Dec 20227:00 amRNSTrading Update
1st Dec 202212:40 pmRNSTotal Voting Rights
28th Nov 20229:00 amRNSAdditional Listing
1st Nov 20221:26 pmRNSTotal Voting Rights
28th Oct 20229:00 amRNSAdditional Listing
12th Oct 20227:19 amRNSTemporary Cost-Plus Revenue Limit and CfD
3rd Oct 20221:38 pmRNSBlock listing Interim Review - SAYE
3rd Oct 20221:36 pmRNSBlock listing Interim Review - PSP
3rd Oct 20221:36 pmRNSBlock listing Interim Review - LTIP 2020
3rd Oct 20221:31 pmRNSBlock listing Interim Review - DSP
3rd Oct 20221:22 pmRNSTotal Voting Rights
3rd Oct 20227:00 amRNSAcquisition of Remaining Interest in Pellet JV
29th Sep 20229:00 amRNSAdditional Listing
13th Sep 20229:35 amRNSTotal Voting Rights
23rd Aug 20229:40 amRNSAdditional Listing
3rd Aug 20224:00 pmRNSAcquisition of 90,000 tonnes Canadian pellet plant
1st Aug 202211:46 amRNSTotal Voting Rights
26th Jul 20227:00 amRNSHalf-year Report
20th Jul 202211:43 amRNSNotice of Results
15th Jul 20224:48 pmRNSHolding(s) in Company
6th Jul 20225:46 pmRNSUpdated expectations for full year 2022
6th Jul 20225:41 pmRNSExtension of coal operations at request of UK Gov
1st Jul 202210:43 amRNSTotal Voting Rights
28th Jun 202211:30 amRNSNotice of Change to Director Details
6th Jun 20223:01 pmRNSTotal Voting Rights
17th May 202211:34 amRNSHolding(s) in Company
12th May 20229:00 amRNSAdditional Listing
4th May 202211:03 amRNSDirector/PDMR Shareholding
3rd May 20225:03 pmRNSTotal Voting Rights
27th Apr 20223:19 pmRNSResult of AGM
27th Apr 20227:00 amRNSTrading Update
26th Apr 202212:20 pmRNSHolding(s) in Company
19th Apr 202212:00 pmRNS2022 Performance Awards - EPS Condition
8th Apr 202211:13 amRNSBlock listing Interim Review - SAYE
8th Apr 202211:11 amRNSBlock listing Interim Review - PSP
8th Apr 202211:10 amRNSBlock listing Interim Review - LTIP 2020
8th Apr 202211:08 amRNSBlock listing Interim Review - DSP
6th Apr 20223:30 pmRNSDirector/PDMR Shareholding
6th Apr 20229:00 amRNSTotal Voting Rights
30th Mar 20229:00 amRNSDirector/PDMR Shareholding
21st Mar 202210:00 amRNSDirector/PDMR Shareholding
17th Mar 20221:34 pmRNSMailing of Annual Report and Notice of AGM
16th Mar 20229:00 amRNSAdditional Listing
1st Mar 202212:39 pmRNSTotal Voting Rights
24th Feb 20227:00 amRNSAnnual Financial Report
23rd Feb 20229:00 amRNSCapacity Market Agreements
16th Feb 20222:40 pmRNSNotice of Results
7th Feb 20228:30 amRNSAdditional Listing
2nd Feb 20229:27 amRNSTotal Voting Rights
28th Jan 202212:25 pmRNSResult of audit tender

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.